Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

Core Insights - Akoya Biosciences and Enable Medicine have announced a collaboration to create the largest commercially available single-cell spatial proteomics atlas, which includes over 100 million single cells from more than 8,500 samples across 15+ cancer types [1][2][3] Group 1: Enable Pan-Cancer Atlas Features - The Enable Atlas is a multi-modal dataset built using Akoya's PhenoCycler-Fusion platform, featuring the PhenoCode™ Discovery IO60 panel as foundational data [2] - It includes rich cellular features with up to 60 protein biomarkers, H&E images, spatial transcriptomics measurements, and comprehensive clinical metadata [2][5] - The dataset is curated, standardized, and commercially licensable, providing immediate value to biopharma researchers and AI model developers [3][5] Group 2: Benefits for Biopharma and Research - The Enable Atlas allows biopharma customers to generate new hypotheses, increase statistical power, and identify novel cellular phenotypes at an unprecedented scale [4] - It is designed for discovery and offers unmatched scale and depth with over 100 million spatially profiled single cells [8] - The dataset's analytical capabilities enable biomarker discovery, comparative analysis, and statistical validation in both discovery and translational research [5][6] Group 3: Upcoming Showcase - The Enable Atlas will be showcased at the American Association for Cancer Research (AACR) Annual Meeting, providing attendees with a first look at this new spatial proteomics resource [8][9] - A live demonstration will be available during the event, with team members present to discuss applications in translational research, biomarker discovery, and drug development [9]